
Medical Technology Ambition in Malaysia: From Manufacturing Base to High-Value MedTech and Healthcare Hub
Introduction
Malaysia has established itself as a significant medical device manufacturing and exporting hub, supported by its developed industrial infrastructure, skilled workforce and strategic location within Southeast Asia. In 2025, Malaysia’s medical device exports reached RM34.54 billion, reflecting the industry’s importance to the national economy and global medical supply chains.1
While manufacturing remains a cornerstone of the industry, Malaysia is increasingly positioning itself to participate in higher-value medical technology (“MedTech”) activities, including research and development (“R&D”), advanced medical devices, digital healthcare and technological innovation.
This transition is supported by government industrial policies, investment incentives and an evolving regulatory framework. However, Malaysia’s ability to realise its ambition of becoming a regional MedTech and healthcare hub will depend on continued investment, regulatory efficiency and the development of domestic technological capabilities.
Malaysia’s Established MedTech Industry and Competitive Advantages
Malaysia’s medical device industry has developed a strong manufacturing base, supported by both multinational corporations and domestic manufacturers. The industry encompasses a wide range of products, from medical gloves and surgical instruments to advanced diagnostic equipment, implantable devices and other specialised medical technologies.
The country’s established supporting industries, particularly electrical and electronics, precision engineering, plastics and rubber manufacturing, provide an integrated supply chain for medical device production. These capabilities, together with Malaysia’s geographical position and access to regional markets, contribute to its attractiveness as a manufacturing and distribution centre.
According to the Malaysian Investment Development Authority (“MIDA”), the medical device industry recorded RM4.0 billion in approved investments across 46 projects in 2025, of which RM3.4 billion comprised foreign investments.2
Notwithstanding these strengths, Malaysia’s next phase of development will require greater participation in higher-value activities, particularly product design, R&D and the commercialisation of innovative medical technologies.
Government Policies and Investment Opportunities in Malaysia’s MedTech Sector
Recognising the importance of the medical device industry, the Malaysian Government has introduced various initiatives to promote advanced manufacturing and attract higher-value investments.
The New Industrial Master Plan 2030 (“NIMP 2030”) identifies medical devices as a priority industry, with particular emphasis on strengthening technological capabilities, encouraging innovation and increasing participation in higher-value activities.3 Among the opportunities identified are advanced medical devices such as robotic surgical equipment, cardiovascular devices and wearable medical technologies.
An important development is the introduction of Malaysia’s New Incentive Framework (“NIF”), which took effect on 1 March 2026 for new manufacturing incentive applications4. The NIF adopts an outcome-based approach, linking investment incentives to measurable outcomes, namely increasing economic complexity, creating high-value jobs, extending domestic supply-chain linkages, developing industrial clusters, improving inclusivity and enhancing sustainability practices.
For MedTech investors, this framework presents opportunities to obtain incentives for qualifying investments that contribute to Malaysia’s industrial development objectives. However, eligibility and the extent of incentives will depend on the nature of the proposed investment and its ability to satisfy the applicable assessment criteria.
Malaysia also maintains a relatively liberal foreign investment policy in its manufacturing sector. Since June 2003, foreign investors have generally been permitted to hold 100% equity in new manufacturing projects, as well as expansion and diversification projects, subject to applicable regulatory requirements.5
However, investors must also consider the manufacturing licensing requirements under the Industrial Co-ordination Act 1975. Manufacturing companies with shareholders’ funds of RM2.5 million or more, or employing 75 or more full-time paid employees, are generally required to obtain a manufacturing licence from the Ministry of Investment, Trade and Industry (“MITI”), with applications submitted through MIDA.6
These policies provide an established framework for foreign MedTech companies seeking to establish or expand their manufacturing operations in Malaysia.
Legal and Regulatory Framework Governing Medical Devices in Malaysia
In addition to investment-related requirements, businesses operating in Malaysia’s MedTech industry must comply with the regulatory framework governing medical devices.
The principal legislation comprises the Medical Device Act 2012 (Act 737), the Medical Device Authority Act 2012 (Act 738) and the Medical Device Regulations 2012. These are supplemented by subsidiary legislation, including the Medical Device (Exemption) Order 2024, the Medical Device (Duties and Obligations of Establishments) Regulations 2019 and the Medical Device (Advertising) Regulations 2019. The Medical Device Authority (“MDA”) is responsible for regulating medical devices and overseeing compliance with the applicable requirements.7
Under section 5 of Act 737, medical devices must generally be registered with the MDA before they may be imported, exported or placed on the Malaysian market, subject to applicable exemptions. In addition, under section 15 of Act 737, establishments that import, export or place medical devices on the market, namely manufacturers, authorised representatives, importers and distributors, must hold an establishment licence issued by the MDA. A manufacturer whose principal place of business is outside Malaysia must appoint an authorised representative in Malaysia.8 Medical devices are classified into four risk categories, namely Classes A (lowest risk), B, C and D (highest risk), under the rules of classification in the Medical Device Regulations 2012, with separate rules applying to in vitro diagnostic medical devices.9 The applicable conformity assessment requirements are determined by the device’s risk classification.
Certain categories of medical devices, including devices intended exclusively for export, clinical research or performance evaluation, custom-made devices and special access medical devices, may qualify for exemption from registration, subject to the relevant conditions and an application to the MDA, under the Medical Device (Exemption) Order 2024 [P.U.(A) 78/2024], which came into operation on 6 March 2024 and replaced the Medical Device (Exemption) Order 2016.10
Regional Regulatory Cooperation
Malaysia has also taken steps to facilitate regional market access through regulatory cooperation with neighbouring countries.
In March 2026, Malaysia and Singapore implemented their Medical Device Regulatory Reliance Programme following a successful six-month pilot.11 Under the programme, eligible medical devices registered with either country’s regulatory authority may benefit from an expedited registration pathway in the other jurisdiction.
Similarly, the Malaysia–Thailand Medical Device Regulatory Reliance Programme was fully implemented on 1 May 2026, facilitating streamlined registration procedures for eligible Class B, C and D medical devices.12
Although these arrangements do not eliminate national regulatory requirements, they may reduce duplicative assessments and shorten registration timelines. However, the arrangements are currently limited to Singapore and Thailand. Further, Singapore’s abridged pathway applies only to devices that have completed full conformity assessment in Malaysia, and not to devices registered in Malaysia through a reliance route.13 Manufacturers seeking to use Malaysia as a base for regional supply would therefore be better placed if their devices undergo full conformity assessment in Malaysia.
Beyond Manufacturing: Opportunities for an Integrated MedTech and Healthcare Hub
Malaysia’s ambitions extend beyond medical device manufacturing towards the development of an integrated ecosystem encompassing medical technology innovation and healthcare services.
Technological advancements present opportunities in areas such as AI-assisted diagnostics, medical robotics, wearable devices and digital healthcare solutions. The development of these technologies will increasingly require collaboration between manufacturers, research institutions, technology companies and healthcare providers.
Malaysia’s established healthcare infrastructure, including private hospitals and specialist medical facilities, provides a potential foundation for such collaboration. Healthcare providers can contribute to the evaluation and adoption of innovative medical technologies, while manufacturers and technology developers can develop solutions addressing clinical needs.
Malaysia’s medical tourism industry also presents opportunities for growth. According to the Malaysia External Trade Development Corporation (“MATRADE”), the country’s private healthcare sector received 1.84 million international patients in 2025, generating RM3.34 billion in revenue.14
Nevertheless, businesses seeking to establish healthcare operations must recognise the distinction between medical device regulation and healthcare service regulation.
While medical devices are principally regulated under Act 737, the establishment and operation of private healthcare facilities are governed by the Private Healthcare Facilities and Services Act 1998 (Act 586). Depending on the proposed activities, healthcare operators may be required to obtain the relevant approvals, licences or registrations from the Ministry of Health. Investors should also note that the liberal equity policy discussed in Section 3 applies to the manufacturing sector. Foreign equity participation in private healthcare facilities is instead subject to approval by the Ministry of Health’s Special Committee on Foreign Equity Participation.15
Challenges and Considerations for Malaysia’s MedTech Development
Despite Malaysia’s established strengths, several challenges remain in its transition towards a high-value MedTech hub.
First, regulatory compliance may involve substantial costs and administrative requirements, particularly for companies introducing innovative medical devices or seeking approvals across multiple jurisdictions. Although regional regulatory cooperation represents positive progress, differences between national regulatory frameworks continue to present challenges.
Second, greater investment in R&D, intellectual property development and specialised technical expertise is necessary to strengthen Malaysia’s capacity to develop and commercialise proprietary medical technologies.
Third, Malaysia faces competition from other regional investment destinations seeking to attract advanced manufacturing and technology companies. This competition is no longer decided by tax incentives alone. Malaysia’s global minimum tax rules have applied, for financial years beginning on or after 1 January 2025, to multinational groups with consolidated revenues of EUR 750 million or more in at least two of the four preceding financial years. These rules reduce the value of conventional tax exemptions for the largest investors and were one of the factors behind the NIF’s move to an outcome-based model.16
Conclusion: Malaysia’s Path Towards a High-Value MedTech Hub
Malaysia possesses a strong foundation for developing into a high-value MedTech and healthcare hub, supported by its established manufacturing ecosystem, strategic location and growing healthcare industry.
Government initiatives under NIMP 2030, the introduction of the NIF and recent developments in medical device regulatory cooperation provide further opportunities to attract investment and facilitate industry growth.
Nevertheless, achieving this ambition will require more than expanding manufacturing capacity. Malaysia must continue strengthening its innovation capabilities, technological expertise and regulatory efficiency to support higher-value activities.
Ultimately, Malaysia’s long-term competitiveness will depend on its ability to integrate manufacturing, innovation and healthcare services within a sustainable and internationally competitive MedTech ecosystem.
1. https://www.matrade.gov.my/en/about-matrade/press-release/matrade-spearheads-delegation-of-malaysian-companies-to-international-healthcare-week-bangkok-2026.
2. https://www.mida.gov.my/wp-content/uploads/2026/03/MIDA_IPR.2025.pdf.
3. https://www.nimp2030.gov.my/nimp2030/modules_resources/bookshelf/e-05-Sectoral_NIMP-Medical_Devices_Industry/e-05-Sectoral_NIMP-Medical_Devices_Industry.pdf.
4. https://www.mida.gov.my/media-release/new-incentive-framework-nif/.
5. Malaysian Investment Development Authority (MIDA), Guidelines on Equity Policy in the Manufacturing Sector, available at https://www.mida.gov.my/setting-up-content/equity-policy-protect-foreign-investment/.
6. https://www.mida.gov.my/setting-up-content/approvals-and-licensing/.
7. https://mda.gov.my/index.php/industry/establishment-licence/establishment-license-information.
8. https://mda.gov.my/index.php/industry/establishment-licence/establishment-license-information.
9. https://portal-disaster.mda.gov.my/index.php/documents/guidance-documents/1978-mda-gd0009-classification-of-general-medical-device.
10. https://www.mda.gov.my/index.php/industry/exemption/announcement.
11. https://www.hsa.gov.sg/medical-devices/international-collaboration-medical-devices/regulatory-reliance.
12. https://www.mda.gov.my/index.php/ms/pengumuman/1795-joint-pengumuman-by-medical-device-authority-mda-malaysia-and-thai-food-and-drug-administration-thai-fda-thailand-on-1-may-2026.
13. https://www.hsa.gov.sg/medical-devices/international-collaboration-medical-devices/regulatory-reliance.
14. https://www.matrade.gov.my/en/about-matrade/press-release/matrade-spearheads-delegation-of-malaysian-companies-to-international-healthcare-week-bangkok-2026.
15. https://www.mida.gov.my/industries/services/healthcare-services/.
16. https://www.hasil.gov.my/antarabangsa/global-minimum-tax-gmt/gmt-guidelines-faq/.
Written by:
Airene Ho Eu Ghee (Senior Counsel) aireneho@azmilaw.com
George Law Ngo Jun (Associate) george.law@azmilaw.com
Corporate Communications, Azmi & Associates – 14 November 2026

